JP2014514364A5 - - Google Patents

Download PDF

Info

Publication number
JP2014514364A5
JP2014514364A5 JP2014510520A JP2014510520A JP2014514364A5 JP 2014514364 A5 JP2014514364 A5 JP 2014514364A5 JP 2014510520 A JP2014510520 A JP 2014510520A JP 2014510520 A JP2014510520 A JP 2014510520A JP 2014514364 A5 JP2014514364 A5 JP 2014514364A5
Authority
JP
Japan
Prior art keywords
compstatin analog
peg
acid
formula
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014510520A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014514364A (ja
JP6522337B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/037648 external-priority patent/WO2012155107A1/en
Publication of JP2014514364A publication Critical patent/JP2014514364A/ja
Publication of JP2014514364A5 publication Critical patent/JP2014514364A5/ja
Application granted granted Critical
Publication of JP6522337B2 publication Critical patent/JP6522337B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014510520A 2011-05-11 2012-05-11 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用 Active JP6522337B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161484836P 2011-05-11 2011-05-11
US61/484,836 2011-05-11
PCT/US2012/037648 WO2012155107A1 (en) 2011-05-11 2012-05-11 Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017111625A Division JP6653294B2 (ja) 2011-05-11 2017-06-06 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用

Publications (3)

Publication Number Publication Date
JP2014514364A JP2014514364A (ja) 2014-06-19
JP2014514364A5 true JP2014514364A5 (https=) 2018-11-29
JP6522337B2 JP6522337B2 (ja) 2019-05-29

Family

ID=47139714

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014510520A Active JP6522337B2 (ja) 2011-05-11 2012-05-11 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用
JP2017111625A Active JP6653294B2 (ja) 2011-05-11 2017-06-06 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用
JP2019129901A Active JP6905554B2 (ja) 2011-05-11 2019-07-12 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017111625A Active JP6653294B2 (ja) 2011-05-11 2017-06-06 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用
JP2019129901A Active JP6905554B2 (ja) 2011-05-11 2019-07-12 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用

Country Status (13)

Country Link
US (5) US10125171B2 (https=)
EP (2) EP2707384B1 (https=)
JP (3) JP6522337B2 (https=)
CN (2) CN107050422B (https=)
AU (3) AU2012253294B2 (https=)
BR (1) BR112013028816B1 (https=)
CA (1) CA2835627C (https=)
DK (1) DK2707384T3 (https=)
ES (1) ES2915265T3 (https=)
IL (3) IL265344B2 (https=)
MX (2) MX356528B (https=)
RU (1) RU2653439C9 (https=)
WO (1) WO2012155107A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
EP2461241A1 (en) 2010-12-03 2012-06-06 Research In Motion Limited Soft key with main function and logically related sub-functions for touch screen device
MX356528B (es) 2011-05-11 2018-06-01 Apellis Pharmaceuticals Inc Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y usos de los mismos.
MX366404B (es) * 2012-11-15 2019-07-08 Apellis Pharmaceuticals Inc Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y composiciones y metodos relacionados.
WO2014078622A1 (en) * 2012-11-15 2014-05-22 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
EP3262410B1 (en) * 2015-02-27 2024-08-14 The Johns Hopkins University Assay to diagnose and treat disorders of the alternative pathway of complement activation
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
US11903994B2 (en) * 2015-10-07 2024-02-20 Apellis Pharmaceuticals, Inc. Dosing regimens
HK1257499A1 (zh) 2015-11-12 2019-10-25 Graybug Vision, Inc. 用於治疗的聚集性微粒
CN105777893B (zh) * 2016-03-24 2019-10-25 杭州亚慧生物科技有限公司 一种高强度血清白蛋白骨修复材料及其制备方法
RU2019113301A (ru) * 2016-10-17 2020-11-17 Апеллис Фармасьютикалс, Инк. Комбинированная терапия для ингибирования с3
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
IL269844B2 (en) 2017-04-07 2025-01-01 Apellis Pharmaceuticals Inc Dosage regimens and related compositions and methods
AU2018265415A1 (en) 2017-05-10 2019-10-31 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
EP3661493A4 (en) 2017-08-02 2021-04-14 Achillion Pharmaceuticals, Inc. THERAPY PLANS FOR TREATMENT OF PAROXYSMALER NIGHTLY HEMOGLOBINURIA
CN107722262B (zh) * 2017-09-18 2020-11-24 华南理工大学 一种聚碳二亚胺类聚合物及其制备方法与应用
WO2019118938A1 (en) 2017-12-15 2019-06-20 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
EP4011905A3 (en) 2018-04-06 2022-06-29 The Trustees Of The University Of Pennsylvania Compstatin analogs with increased solubility and improved pharmacokinetic properties
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
WO2020051538A1 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ, インコーポレーテッド 医学的障害の治療のための大環状化合物
KR20210093855A (ko) 2018-09-25 2021-07-28 아칠리온 파르마세우티칼스 인코포레이티드 보체 인자 d 억제제의 형태체 형태
WO2020131974A1 (en) 2018-12-17 2020-06-25 Achillion Pharmaceuticals, Inc. Targeted dosing for the treatment of complement mediated disorders
BR112021018456A2 (pt) 2019-03-22 2021-11-23 Achillion Pharmaceuticals Inc Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento
US11510939B1 (en) 2019-04-19 2022-11-29 Apellis Pharmaceuticals, Inc. RNAs for complement inhibition
CN110624274B (zh) * 2019-08-27 2021-04-13 苏州赛分科技有限公司 分离介质及其制备方法和应用
CN115362162A (zh) 2020-02-20 2022-11-18 艾其林医药公司 用于治疗补体因子d介导的障碍的杂芳基化合物
CN116437913A (zh) 2020-09-23 2023-07-14 艾其林医药公司 用于治疗补体介导的病症的药物化合物
AU2022383173A1 (en) * 2021-11-03 2024-05-23 Apellis Pharmaceuticals, Inc. Complement inhibitor dosing regimens
CN118812653A (zh) * 2023-04-18 2024-10-22 成都奥达生物科技有限公司 一种长效坎普他汀化合物
WO2025176843A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof
WO2026083442A1 (en) 2024-10-15 2026-04-23 Mylan Laboratories Limited Process for the preparation of pegcetacoplan and its purification using chromatography

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2295746A1 (fr) 1974-12-23 1976-07-23 Francaise Coop Pharma Nouveaux derives du tryptophane a activite nerveuse centrale renforcee
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IT1179866B (it) 1984-12-12 1987-09-16 Rotta Research Lab Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono
US4576750A (en) 1985-04-22 1986-03-18 Merck & Co., Inc. Tryptophan derivative
EP1413587A2 (en) 1991-05-03 2004-04-28 Washington University Modified complement system regulator
US5776970A (en) 1994-04-28 1998-07-07 Yeda Research And Development Co. Ltd. Tryptophan derivatives as protein tyrosine kinase blockers and their use in the treatment of neoplastic diseases
US6319897B1 (en) 1996-03-13 2001-11-20 John D. Lambris Peptides which inhibit complement activation
JP2002503223A (ja) 1997-04-11 2002-01-29 アドバンスト・メディシン・インコーポレイテッド 複数の活性分子を供与する分子
AU6957098A (en) 1997-04-11 1998-11-11 Advanced Medicine, Inc. Polyvalent presenter combinatorial libraries and their uses
US6169057B1 (en) 1997-09-04 2001-01-02 The Regents Of The University Of California Use of tryptophan and analogs as plant growth regulators
AU3485999A (en) 1998-04-10 1999-11-01 Mayo Foundation For Medical Education And Research Neo-tryptophan
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
PT1549333E (pt) 2002-09-20 2012-01-03 Univ Pennsylvania Análogos de compstatina com actividade melhorada
EP2662089A3 (en) 2005-10-08 2014-02-19 Potentia Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US20070134244A1 (en) 2005-10-14 2007-06-14 Alcon, Inc. Combination treatment for pathologic ocular angiogenesis
SG10201804008UA (en) * 2005-11-04 2018-06-28 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
CN102977191B (zh) 2005-11-28 2016-08-10 宾夕法尼亚州大学理事会 有效的c3补体抑制素类似物
CL2007003044A1 (es) 2006-10-24 2008-07-04 Wyeth Corp Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros.
HUE026001T2 (en) 2007-02-05 2016-04-28 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
CA2691002C (en) 2007-07-19 2016-05-10 Allexcel, Inc. Self-assembling amphiphilic polymers as anticancer agents
WO2009015087A2 (en) 2007-07-20 2009-01-29 Potentia Pharmaceuticals, Inc. Compositions and methods for treatment of trauma
BRPI0817524A2 (pt) 2007-10-02 2017-05-02 Potentia Pharmaceuticals Inc liberação prolongada de análogos de compstatina provenientes de géis
US20110190221A1 (en) * 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
CA2760839C (en) 2009-05-01 2019-02-12 The Trustees Of The University Of Pennsylvania Modified compstatin with peptide backbone and c-terminal modifications
WO2010135717A2 (en) 2009-05-21 2010-11-25 Potentia Pharmaceuticals, Inc. Complement assays and uses thereof
EP2338520A1 (de) 2009-12-21 2011-06-29 Ludwig Maximilians Universität Konjugat mit Zielfindungsligand und dessen Verwendung
US8625635B2 (en) 2010-04-26 2014-01-07 Cleversafe, Inc. Dispersed storage network frame protocol header
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
US20130324482A1 (en) 2010-07-09 2013-12-05 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
CA2813049A1 (en) 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
MX356528B (es) 2011-05-11 2018-06-01 Apellis Pharmaceuticals Inc Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y usos de los mismos.
EP3524258B1 (en) 2011-06-22 2025-10-01 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
CA2847862C (en) 2011-09-07 2021-01-12 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved pharmacokinetic properties
WO2014028861A1 (en) 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
WO2014078734A2 (en) 2012-11-15 2014-05-22 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
MX366404B (es) 2012-11-15 2019-07-08 Apellis Pharmaceuticals Inc Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y composiciones y metodos relacionados.
US9512180B2 (en) 2012-12-19 2016-12-06 The Regents Of The University Of California Compstatin analogs
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
JP6159886B2 (ja) 2013-07-16 2017-07-05 北京机械▲設▼▲備▼研究所 高層及び超高層ビルの消火活動に適用する消防車
US9806963B2 (en) 2013-10-18 2017-10-31 Cellco Partnership Feature activation on device
IL269844B2 (en) 2017-04-07 2025-01-01 Apellis Pharmaceuticals Inc Dosage regimens and related compositions and methods

Similar Documents

Publication Publication Date Title
JP2014514364A5 (https=)
US20230127248A1 (en) Peptidomimetic macrocycles and formulations thereof
JP2017155056A5 (https=)
CN104684576B (zh) 聚乙二醇化的oxm变体
CN113956348B (zh) 胰高血糖素和glp-1协同激动剂化合物
JP6522337B2 (ja) 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用
US8580918B2 (en) Peptidic GLP-2 agonists
KR102064142B1 (ko) 이중으로 유도화된 키토산 나노입자 및 이의 제조 방법과 생체 내 유전자 도입을 위하여 이를 이용하는 방법
US7410949B2 (en) Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
ES2381497T3 (es) Agonistas del receptor del neuropéptido-2
CN110022902A (zh) 包含glp-1/胰高血糖素双重激动剂、接头和透明质酸的缀合物
TW201209062A (en) Amide based glucagon superfamily peptide prodrugs
JP2011511778A5 (https=)
US20180371044A1 (en) Peptidomimetic macrocycles
WO2007133778A2 (en) Methods to restore glycemic control
JP2019511497A5 (https=)
UA129395C2 (uk) Ацильовані сполуки інсуліну пролонгованої дії
US20100016550A1 (en) Methods for Site-Specific Pegylation
JP2015517458A (ja) 医薬組成物
EP3302571B1 (en) Pegylated oxyntomodulin variants
US10010580B2 (en) Insulin independence among patients with diabetes utilizing an optimized hamster Reg3 gamma peptide
US20190160152A1 (en) Long-acting oxyntomodulin formulation and methods of producing and administering same
JP2005506276A5 (https=)
AU2022329794A1 (en) Human transferrin receptor–binding peptide
JP7022746B2 (ja) インスリン製剤のためのバイオアッセイ